ArticleCancer biomarkers : section A of Disease markers
A novel diagnostic model for early-stage high-grade serous ovarian cancer based on serum tRNA-derived fragments.
Article in Cancer biomarkers : section A of Disease markers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of ovarian cancer, particularly high-grade serous ovarian cancer (HGSOC), remains challenging due to the lack of reliable biomarkers. This study investigated the potential of tRNA-derived small RNAs (tsRNAs) as non-invasive diagnostic biomarkers using liquid biopsy. Using qRT-PCR, we analyzed the relative Ct values of selected tsRNAs in plasma samples from healthy controls and patients with early- and late-stage HGSOC. A logistic regression model constructed using the relative Ct value of the selected tsRNA demonstrated high sensitivity and specificity for distinguishing ovarian cancer patients from healthy controls, including those with early-stage disease. The model was validated in a multi-center cohort, and analysis confirmed the dysregulation of this tsRNA in tumor tissue compared to normal tissue. These findings suggest that this single plasma tsRNA may serve as a promising biomarker for early HGSOC detection, supporting its potential clinical utility pending further mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.